KRAS and cancer: (124) have speculated that GSK-J4, the histone H3K27 demethylase inhibitor, is able to induce oxidative and metabolic stress in cancer cell lines when a KRAS mutation is detected, linking the role of oncogenic KRAS in the metabolic stress response to GSK-J4 sensitivity.